Sector: health
Conviction from: NASDAQ
52-week range: 37.3170.37
Royalty Pharma acquires royalty interests in approved and development-stage prescription drugs, funding biopharmaceutical innovation in exchange for future royalty streams.
4 tracked filer(s) hold this · 0 opened, 2 added, 2 trimmed in 30-SEP-2026
Aggregate 13FScore 71 — mean of 4 scored holder(s) · buyers (new/add) avg 65. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Steve Cohen / Point72 | 75 | Added +954% | 1,123,256 | $65,553,220 | 0.1% |
| Bridgewater | 55 | Added +116% | 474,521 | $27,693,046 | 0.1% |
| Pat Dorsey / Dorsey Asset | 94 | Trimmed -2% | 2,415,667 | $140,978,326 | 8.2% |
| Paul Tudor Jones / Tudor | 61 | Trimmed -16% | 510,736 | $29,806,553 | 0.0% |
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-02-20 | SCHEDULE 13D/A | Severgnini Achille G. | 5.7% | Med | filing |
2 disclosed trade(s) by 1 filer(s).